Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fiorage is a family of sterile, pyrogen-free, non-animal cross-linked hyaluronic acid dermal fillers developed by Espad Pharmed for aesthetic and cosmetic applications. The product line includes several variants—Fiorage S, M, L, and XL—with varying concentrations of hyaluronic acid (ranging from 16 mg/mL to 26 mg/mL) to address different needs such as fine line correction, deep wrinkle filling, and facial volumization. The formulation incorporates lidocaine hydrochloride to reduce patient discomfort during and after injection, and mannitol, which serves as an antioxidant to protect the gel from degradation. Administered via dermal, subcutaneous, or intracutaneous injection, Fiorage works by physically augmenting soft tissue to restore contours and smooth skin depressions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fiorage.